Provided is use of Corydalis saxicola Bunting and a Corydalis saxicola Bunting total alkaloid capsule in the preparation of drugs for treating non-alcoholic fatty liver diseases, non-alcoholic steato-hepatitis, drug induced liver injury, and chemical liver injury.

The present application discloses a process for the purification and concentration of cannabinoids from cannabis inflorescence. Kief, or resinous trichomes, are suspended in water in order to be treated by electrolysis. The mixture is then filtered by an electrically charged depth filter. The mixture is then concentrated via a Tangential Flow Filter. The resulting concentrate may be at least one of THC, THCa, CBD, CBG, CBDV, CBDA, THCV, CBCA, THCVA, CBDVA, and CBCVA.

A method for culturing ginseng cell with high content of ginsenoside, including inducing ginseng cell line: after disinfected and sliced, ultrasonically treating old mountain ginseng, and culturing the old mountain ginseng in a culture medium; screening the ginseng cell line: choosing a variety of culture mediums and using hormones for cell separation and culture, selecting cell lines with better growth morphology and faster growth, and performing solid subculture and liquid suspension culture; optimizing conversion conditions: using acids to treat the chosen cell lines, and controlling the treatment temperature and treatment time, detecting ginsenosides Rg3 and Rh2 in the dried products, determining an optimal treatment condition according to the highest total amount; large-scale industrial production: according to the optimal treatment condition, performing the liquid suspension culture of the selected cell lines and scaling up the scale of culture to obtain large-scale industrial production of ginseng cell products.

The present invention relates to a composition for enhancing immunity or a composition for preventing or ameliorating neurodegenerative diseases, both of which contain, as an active ingredient, a mixture extract of goji berries, mulberries and jujubes or an extract mixture thereof.

The invention relates to a Cleome droserifolia extract for topical application to the skin and/or mucous membranes. The invention also relates to the use of such an extract as well as to a process for obtaining it and to the compositions containing same.

The present disclosure provides a pharmaceutical composition comprising a first pharmaceutically active portion comprising one or more cannabinoids extracted from Cannabis plant material; a second pharmaceutically active portion comprising glutathione extracted from Cannabis plant material and optionally one or more excipients; wherein the molar ratio of the second pharmaceutically active portion to the first pharmaceutically active portion is at least 0.5:1. The present disclosure also provides a method of manufacturing a pharmaceutical composition comprising the steps of: extracting a first fraction containing one or more cannabinoids from a Cannabis plant material using a polar solvent; extracting a second fraction containing from the glutathione from the same Cannabis plant material using water; and drying and combining the first fraction and the second fraction to form the pharmaceutical composition.

Disclosed are a Piper laetispicum extract and a preparation method therefor and a use thereof. The Piper laetispicum extract includes any one or more of sesamin, (2E,6E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)heptadienamide, (2E,4E)-N-isobutyldodecane-2,4-dieneamide, (2E,4E)-N-isobutyl-15-phenylpentadeca-2,4-dieneamide, (2E,4E,14Z)—N-isobutyleicosane-2,4,14-trienamide, and (2E,4E)-N-isobutyl-13-phenyltrideca-2,4-dieneamide. The Piper laetispicum extract can prevent depression.

The present disclosure relates to highly resistant starch compositions, methods for preparing such highly resistant starch compositions, and methods of using such highly resistant starch compositions to treat or prevent a disease or condition associated with dysregulation and/or dysfunction of the intestinal microbiome.

This invention relates to the extraction of psychoactive compounds from psilocybin fungus for use in medicine. Raw psilocybin fungus is dried and ground. The solvent used for extraction is a lower aliphatic alcohol, water, a hydro-alcohol mixture, an acidic hydro-alcohol mixture, or an alkaline hydro-alcohol mixture. The extraction slurry is filtered and pH-adjusted if necessary. The solvent is then partially evaporated, or completely evaporated with water added back, to form a concentrated slurry. The concentrated slurry is then standardized to provide a known concentration of the psychoactive alkaloids that have been extracted. The standardized slurry may then be dried to result in a powdered psilocybin mushroom extract with a precisely defined purity.

This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phyto-pharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment.